Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22669484 | 0.90 | HTT (0.40) | ADAMTS5GRIN1GRIN2BGAAALDH1A1 | |
| SCHEMBL22669126 | 0.89 | MAPK1 (0.39) | GAA | |
| SCHEMBL22669335 | 0.89 | MAOA (0.36) | ADAMTS5GRIN1GRIN2BGAAALDH1A1 | |
| SCHEMBL22668961 | 0.87 | CNR1 (0.38) | CNR1GAAALDH1A1 | |
| SCHEMBL22669514 | 0.86 | ATF4 (0.41) | ADAMTS5GRIN1GRIN2BGAAALDH1A1 | |
| SCHEMBL30025580 | 0.86 | ATF4 (0.46) | ATMCNR1ADAMTS5 | |
| SCHEMBL19569284 | 0.86 | ATF4 (0.46) | ATMCNR1ADAMTS5 | |
| SCHEMBL22669522 | 0.85 | MAPT (0.39) | ADAMTS5GRIN1GRIN2BGAAALDH1A1 | |
| SCHEMBL22669473 | 0.85 | ATF4 (0.41) | ROCK2ADAMTS5ROCK1 | |
| SCHEMBL22669139 | 0.84 | HPGD (0.39) | ADAMTS5GRIN1GRIN2BGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATM 114/4885ROCK2 2906/4885CNR1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.